中国药业2017，Vol.26Issue(15)：83-85,3.DOI:10.3969/j.issn.1006-4931.2017.15.030
多西紫杉醇治疗可切除淋巴结阳性乳腺癌30例疗效与安全性观察
Clinical Efficacy and Safety of Docetaxel for Treating Resectable Lymph Node Positive Breast Cancer in 30 Cases
摘要
Abstract
Objective To investigate the clinical efficacy and safety of docetaxel in treating resectable lymph node positive breast can-cer. Methods Totally 60 axillary lymph node positive patients underwent modified radical mastectomy in our hospital in 2015 were di-vided into the control group and the observation group according to parallel random sampling method, 30 cases in each group. The con-trol group was treated with epirubicin combined with fluorouracil and cyclophosphamide ( FEC ) , and the observation group was treated with chemotherapy with docetaxel ( TEC ) . The recent curative effects and the toxicity of two groups were compared. Results The total effective rate and the disease control rate of the observation group were 46. 67%, 83. 33%, respectively, which were significantly higher than 16. 67% and 66. 67% of the control group ( P < 0. 05 ) . The incidence rate of peripheral nerve reaction, bone marrow toxicity and digestive system reaction in the observation group were significantly lower than those in the control group ( P < 0. 05 ) . Conclusion Do-cetaxel in the treatment of resectable lymph node positive breast cancer has good effect and less toxicity, it can be used as the preferred drug for the disease in clinic.关键词
多西紫杉醇/毒副反应/乳腺癌/临床疗效Key words
docetaxel/toxicity/breast cancer/clinical effect分类
医药卫生引用本文复制引用
殷培超,徐永萍..多西紫杉醇治疗可切除淋巴结阳性乳腺癌30例疗效与安全性观察[J].中国药业,2017,26(15):83-85,3.
